Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Evaluation of Hepatotoxicity with Treatment Doses of Flucytosine and Amphotericin B for Invasive Fungal Infections.

Folk A, Cotoraci C, Balta C, Suciu M, Herman H, Boldura OM, Dinescu S, Paiusan L, Ardelean A, Hermenean A.

Biomed Res Int. 2016;2016:5398730. doi: 10.1155/2016/5398730. Epub 2016 Feb 2.

2.

Clinical Immunophenotype at Disease Onset in Previously Healthy Patients With Cryptococcal Meningitis.

Xu L, Huang Q, Lin JR, Zhu CY, Li XH, Ye SK, Zhu AH, Chen DH, Zhang CF, Chen L, Ling Y.

Medicine (Baltimore). 2016 Feb;95(6):e2744. doi: 10.1097/MD.0000000000002744.

3.

Combination of Amphotericin B and Flucytosine against Neurotropic Species of Melanized Fungi Causing Primary Cerebral Phaeohyphomycosis.

Deng S, Pan W, Liao W, de Hoog GS, Gerrits van den Ende AH, Vitale RG, Rafati H, Ilkit M, Van der Lee AH, Rijs AJ, Verweij PE, Seyedmousavi S.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2346-51. doi: 10.1128/AAC.02526-15. Print 2016 Apr.

PMID:
26833164
4.

Fighting the Monster: Applying the Host Damage Framework to Human Central Nervous System Infections.

Panackal AA, Williamson KC, van de Beek D, Boulware DR, Williamson PR.

MBio. 2016 Jan 26;7(1):e01906-15. doi: 10.1128/mBio.01906-15. Review.

5.

Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.

Twitty CG, Diago OR, Hogan DJ, Burrascano C, Ibanez CE, Jolly DJ, Ostertag D.

Hum Gene Ther Methods. 2016 Feb;27(1):17-31. doi: 10.1089/hgtb.2015.106. Epub 2015 Dec 1.

PMID:
26467507
6.

Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.

Bicanic T, Bottomley C, Loyse A, Brouwer AE, Muzoora C, Taseera K, Jackson A, Phulusa J, Hosseinipour MC, van der Horst C, Limmathurotsakul D, White NJ, Wilson D, Wood R, Meintjes G, Harrison TS, Jarvis JN.

Antimicrob Agents Chemother. 2015 Dec;59(12):7224-31. doi: 10.1128/AAC.01698-15. Epub 2015 Sep 8.

8.

Epidemiological characterization and prognostic factors in patients with confirmed cerebral cryptococcosis in central Taiwan.

Chen CH, Sy HN, Lin LJ, Yen HC, Wang SH, Chen WL, Chen YM, Chang YJ.

J Venom Anim Toxins Incl Trop Dis. 2015 May 12;21:12. doi: 10.1186/s40409-015-0012-0. eCollection 2015.

9.
10.

Cryptococcosis diagnosis and treatment: What do we know now.

Perfect JR, Bicanic T.

Fungal Genet Biol. 2015 May;78:49-54. doi: 10.1016/j.fgb.2014.10.003. Epub 2014 Oct 13. Review.

11.

Treatment and outcomes among patients with Cryptococcus gattii infections in the United States Pacific Northwest.

Smith RM, Mba-Jonas A, Tourdjman M, Schimek T, DeBess E, Marsden-Haug N, Harris JR.

PLoS One. 2014 Feb 19;9(2):e88875. doi: 10.1371/journal.pone.0088875. eCollection 2014.

12.

Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, Mofenson LM, Nesheim S; Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children, National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association of the Infectious Diseases Society of America, Pediatric Infectious Diseases Society, American Academy of Pediatrics.

Pediatr Infect Dis J. 2013 Nov;32 Suppl 2:i-KK4. doi: 10.1097/01.inf.0000437856.09540.11. No abstract available.

13.

Inhibition of nucleotide biosynthesis potentiates the antifungal activity of amphotericin B.

Banerjee D, Burkard L, Panepinto JC.

PLoS One. 2014 Jan 30;9(1):e87246. doi: 10.1371/journal.pone.0087246. eCollection 2014.

14.

ASDCD: antifungal synergistic drug combination database.

Chen X, Ren B, Chen M, Liu MX, Ren W, Wang QX, Zhang LX, Yan GY.

PLoS One. 2014 Jan 24;9(1):e86499. doi: 10.1371/journal.pone.0086499. eCollection 2014.

15.

Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days.

Livermore J, Howard SJ, Sharp AD, Goodwin J, Gregson L, Felton T, Schwartz JA, Walker C, Moser B, Müller W, Harrison TS, Perfect JR, Hope WW.

MBio. 2014 Jan 28;5(1):e00725-13. doi: 10.1128/mBio.00725-13.

16.

An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.

Kumar A.

Virulence. 2014 Jan 1;5(1):80-97. doi: 10.4161/viru.26913. Epub 2013 Nov 1. Review.

17.

Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal.

Loyse A, Dromer F, Day J, Lortholary O, Harrison TS.

J Antimicrob Chemother. 2013 Nov;68(11):2435-44. doi: 10.1093/jac/dkt221. Epub 2013 Jun 20. Review.

18.

Predictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune status.

Brizendine KD, Baddley JW, Pappas PG.

PLoS One. 2013;8(3):e60431. doi: 10.1371/journal.pone.0060431. Epub 2013 Mar 26.

19.

Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis.

Bratton EW, El Husseini N, Chastain CA, Lee MS, Poole C, Stürmer T, Weber DJ, Juliano JJ, Perfect JR.

Antimicrob Agents Chemother. 2013 Jun;57(6):2485-95. doi: 10.1128/AAC.01800-12. Epub 2013 Mar 11.

20.

Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis.

Seyedmousavi S, Melchers WJ, Mouton JW, Verweij PE.

Antimicrob Agents Chemother. 2013 Apr;57(4):1866-71. doi: 10.1128/AAC.02226-12. Epub 2013 Feb 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk